The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 studyMikkel Rosendahl, Michael Andersson, Henrik Lindman et al.|European Journal of Cancer|2009Cited by 21
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1Per Edlund, Carl Blomqvist, Johan Ahlgren et al.|Acta Oncologica|2011Cited by 11
A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer.Henrik Lindman, Carl Blomqvist, Jonas Bergh et al.|Journal of Clinical Oncology|2011Cited by 5